Transcept Pharmaceuticals | Evaluate

January 19, 2015

2014 sets post-crash venture record, but you ain’t seen nothing yet

Oblivion beckons for Remodulin as FDA again says no

January 03, 2013

Pharma data news over the Christmas period

December 06, 2012

Investors kick Chelsea after it trips on its Northera data again

February 07, 2012

Merck’s new sleep drug has soporific effect on markets

December 13, 2011

Alexza's failure to win broad backing for Adasuve could be last gasp

November 24, 2011

Intermezzo approval not the end of Transcept thriller

November 11, 2011

Nabi's demise and cash could attract IPO hopefuls

September 19, 2011

Transcept and Vivus hoping to buck the trend with another approval chance

September 02, 2011

PDUFA renewal plans include longer reviews and more meetings

July 13, 2011

Intermezzo disappointment another rude awakening for Transcept

Load More